| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
CytomX Therapeutics, Inc.$3.76
-0.23 (-5.69%)
D 25Pipeline Score Overvalued Pharma · Commercial
Market Cap
818.56 M
EPS
-0.36
P/E Ratio
-
Value Trade
11.44 M
SEC Financials
Q1 2026Dilution Risk
Revenue
10.26 M
R&D Expenses
19.24 M
Operating CF
-25.55 M
Total Assets
359.36 M
Total Liabilities
39.41 M
Equity
319.94 M
D/E Ratio
12,345
1.08 %
Week
-21.99 %
1 Month
-29.59 %
3 Month
0 %
6 Month
-55.92 %
5 Year
-76.5 %
All Time
Cash Data
Cash Position
346.71 M
Monthly Burn
8.52 M
Runway
38.8 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.99 M
52 Week Range
1.72 - 8.21
% held by Insiders
15.51 %
% held by Institutions
81.6 %
Enterprise Value
474.71 M
Total Shares
217.61 M
Short %
17.8 %
Float Shares
199.76 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CytomX Therapeutics, Inc.
573Total events
6Upcoming
88Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 6
Dec 2026
T1Topline Readout
Initial clinical data for CX-801 in combination with KEYTRUDA expected by end of 2026
Dec 2026
T2Trial Initiation
Phase 1b/2 combination study with bevacizumab and chemotherapy expected to start by end of 2026
Q1 2027
T2Trial Initiation
Varseta-M potentially advancing into registrational study in late line CRC
Event history 567
Q3 2026
●Trial InitiationCX-2051Trial
Initiation of Phase 1 expansion cohort(s) in additional indications
Q3 2026
▲Trial Initiationvarsetatug masetecanTrial
Phase 1 expansion cohorts in additional EpCAM-expressing indications planned for 2H 2026
EpCAM-expressing cancerssource ↗
Jun 10, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
Jun 4, 2026
Jun 3, 2026
▲Partnership / LicenseCorporate
Expansion of strategic research collaboration with Regeneron for conditional bispecific therapeutics
cancersource ↗
May 18, 2026
Apr 2026
▲Enrollment Completevarsetatug masetecanTrial
Enrollment of 40 patients in Varseta-M Dose Optimization completed
advanced colorectal cancersource ↗
Q2 2026
◆Topline Readoutvarsetatug masetecanClinical Data
Additional Phase 1 Varseta-M data update expected to support monotherapy dose selection and registrational trial design
advanced colorectal cancersource ↗
Q2 2026
◆Trial Initiationvarsetatug masetecanTrial
Phase 1/2 Varseta-M chemotherapy combination study to be initiated
colorectal cancersource ↗
Q2 2026
◆FDA Feedback Receivedvarsetatug masetecanFDA Meeting
FDA interactions targeted for mid-year to align on registrational trial design
advanced colorectal cancersource ↗
Q2 2026
▼Program DiscontinuationCorporate
Astellas chose to not advance remaining preclinical programs under alliance, termination effective Q2 2026
Drug Pipeline Intelligence
D25
Pipeline Score $139M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.6x
rNPV / MCap Top 25%
Micro Cap (rank 684 of 911)
Percentile RankCytomX Therapeutics, Inc. faces pipeline headwinds (25/100), with $347M risk-adjusted pipeline value, led by CX-2009 in Neoplasms (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CX-2009 Small molecule | Neoplasms | Phase 2 | NCT04596150 | 10% | $134M | COMPLETED | 125 | - | - | Jun 2, 2023 | - | Jan 23, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
varsetatug masetecan | advanced colorectal cancer | Phase 1 | 2026-05-07 | 40 total patients across the 8.6 mg/kg Q3W and 10 mg/kg Q3W doses Read More | CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Pa Read More | |
varsetatug masetecan | advanced colorectal cancer | Phase 1 | 2026-05-07 | 40 total patients across the 8.6 mg/kg Q3W and 10 mg/kg Q3W doses Read More | CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Pa Read More | |
varsetatug masetecan | advanced colorectal cancer | Phase 1 | 2026-05-07 | 40 total patients across the 8.6 mg/kg Q3W and 10 mg/kg Q3W doses Read More | CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Pa Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CTMX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CTMX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CTMXCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX Therapeutics has announced an expansion of its collaboration with Regeneron Pharmaceuticals to develop conditional bispecific cancer therapies. Under this expanded agreement, CytomX will receive a $37 million target selection payment for two new programs. Regeneron has the option to select additional targets, which could result in up to $4 billion in potential milestone payments. The collaboration aims to leverage both companies' technologies to create innovative immunotherapies for challenging cancer types.
Read more →CTMXCytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics will present at two investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company aims to showcase its innovative PROBODY therapeutic platform, which focuses on localized cancer treatments. Management will also be available for one-on-one investor meetings during these events.
Read more →CTMXCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics has appointed Mamata Gokhale, Ph.D., as Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy, particularly for its lead program Varseta-M, which is expected to enter a registrational study by mid-2027. Her extensive experience in oncology regulatory affairs is anticipated to enhance CytomX's clinical development efforts.
Read more →CTMXCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Pa
CytomX Therapeutics announced positive outcomes from the Phase 1 Dose Expansion Study of Varseta-M, targeting advanced colorectal cancer, and is focusing on advancing its clinical development. The company reported Q1 2026 financial results, showing $346.7 million in cash but a significant decrease in revenue compared to the prior year. Multiple trials for Varseta-M and plans for ongoing studies underscore its strategic importance for the company's portfolio. Financial performance highlights increased R&D expenses, reflecting investment in the product's development.
Read more →CTMXCytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
CytomX Therapeutics will report its first quarter financial results on May 7, 2026. Following the announcement, a conference call and webcast will be held to discuss the results. The company focuses on developing conditionally activated biologics for cancer treatment, with a robust pipeline of therapeutic candidates.
Read more →CTMX▼ -19.3%on this news
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics has announced a public offering of approximately 46 million shares of common stock priced at $5.30 each, aiming to raise $250 million. The funds will primarily support the development of Varseta-M and other pipeline projects. The offering is expected to close on March 19, 2026, pending customary conditions.
Read more →CTMX▲ +44.2%on this newsshared move
CytomX’s Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
CytomX Therapeutics announced positive Phase 1 expansion data for Varsetatug Masetecan (Varseta-M), a novel EpCAM PROBODY ADC aimed at late-line metastatic colorectal cancer. The data reveal confirmed overall response rates of 32% at the 10 mg/kg dosage and progression-free survival rates of 7.1 months. Ongoing safety evaluations showed a 10% Grade 3 diarrhea rate, while the company aims to discuss registrational trial designs with the FDA later this year. Additionally, future combination studies with chemotherapy and other agents are planned.
Read more →CTMX▲ +44.2%on this newsshared move
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics announced a public offering of $250 million in common stock and pre-funded warrants. The company plans to use the proceeds for the development of its pipeline programs, including Varseta-M. The offering is contingent on market conditions, and underwriters have an option for an additional $37.5 million in shares.
Read more →CTMX▲ +44.2%on this newsshared move
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ADC in Patie
CytomX Therapeutics released its 2025 financial results, highlighting positive outcomes from the Phase 1 dose expansion study of Varseta-M in advanced colorectal cancer. The company aims to engage with the FDA regarding a registrational study design for Varseta-M and has initiated new combination studies. Financially, CytomX reported a revenue decrease due to the conclusion of certain collaborations, while also detailing successful management of expenses. The company maintains a focus on advancing its clinical programs, including the upcoming data from the CX-801 study by 2026.
Read more →CTMX▲ +5.4%on this news
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
CytomX Therapeutics, Inc. will report its full year 2025 financial results on March 16, 2026, before U.S. markets open. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET. CytomX focuses on developing conditionally activated biologics for cancer treatment, with a promising pipeline including Varseta-M and CX-801.
Read more →CTMX▼ -6.6%on this news
CytomX Therapeutics to Present at Upcoming February Conferences
CytomX Therapeutics announced its participation in two significant conferences in February 2026. The Guggenheim Emerging Outlook: Biotech Summit will take place on February 11, and the World ADC London is scheduled for February 25. These events highlight CytomX's commitment to advancing its innovative cancer therapies.
Read more →CTMXCytomX Therapeutics Announces Business Update and Company Milestones for 2026
CytomX Therapeutics provided business updates and milestones for 2026, highlighting progress in their clinical trials for Varsetatug masetecan (Varseta-M) and CX-801. The company anticipates Phase 1 colorectal cancer expansion data for Varseta-M in Q1 2026 and a combination study with bevacizumab. Additionally, CX-801's combination data with KEYTRUDA is expected by year-end 2026. CytomX's CEO expressed optimism about advancing their promising therapies in their pipeline.
Read more →CTMXCytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics, Inc. has announced its participation in two upcoming investor conferences in December 2025. The 8th Annual Evercore Healthcare Conference will take place on December 2 in Coral Gables, FL, followed by the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, NY. During these conferences, CytomX management will engage with investors through presentations and one-on-one meetings.
Read more →CTMX▼ -8.7%on this news
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
CytomX Therapeutics will present at the Jefferies Global Healthcare Conference on November 20, 2025. CEO Sean McCarthy will participate in a fireside chat, and a live webcast will be available. The company is focused on developing conditionally activated biologics for cancer treatment and has a pipeline that includes CX-2051 and CX-801.
Read more →CTMX▼ -13.6%on this news
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
CytomX Therapeutics reported its third quarter 2025 financial results, highlighting progress in its pipeline, particularly with CX-2051 and CX-801. The company is on track for a CX-2051 Phase 1 data update in Q1 2026 and has initiated a combination study with CX-801. However, there was a notable decrease in revenue compared to the previous year.
Read more →CTMXCytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
CytomX Therapeutics announced the presentation of initial Phase 1 data for CX-801 at the SITC Annual Meeting. The data demonstrate tumor-selective interferon signaling activation in advanced melanoma patients. The findings support the ongoing combination study with KEYTRUDA. Initial evidence suggests CX-801 is well tolerated and modulates the immune tumor microenvironment.
Read more →CTMXCytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CytomX Therapeutics, Inc. has announced it will report its third quarter financial results on November 6, 2025, after the U.S. markets close. Following this announcement, the company will host a conference call and webcast to discuss the financials. The event marks a significant update for stakeholders interested in the company's financial performance and future outlook.
Read more →CTMXCytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
CytomX Therapeutics has appointed Rachael Lester as Chief Business Officer. With over 20 years of experience in the biopharmaceutical industry, she will lead the company's strategy and business development efforts. Lester's expertise is expected to enhance CytomX's ability to advance its innovative cancer therapies, particularly through its PROBODY platform.
Read more →CTMXCytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics will participate in several investor conferences in September 2025, including the Cantor Global Healthcare Conference and the H.C. Wainwright Global Investment Conference. The company aims to showcase its innovative biologics designed for cancer treatment. Management will also be available for one-on-one meetings with registered investors.
Read more →CTMXCytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
CytomX Therapeutics has updated on its CX-2051 Phase 1 study, reporting the enrollment of 73 colorectal cancer patients. The study remains active, with ongoing dosing across all expansion doses. The company aims to provide a data update in the first quarter of 2026, emphasizing patient safety as a priority. The update addresses recent social media discussions regarding the study's progress.
Read more →CTMXCytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
CytomX Therapeutics announced its financial results for Q2 2025 along with significant updates on its clinical pipeline. The company reported positive interim data for CX-2051, a first-in-class antibody drug conjugate, in treating advanced colorectal cancer and planned to initiate a Phase 2 study in 2026. CytomX also successfully raised $100 million, enhancing its funding for ongoing clinical development. However, the company saw a decline in total revenues compared to the previous year, attributed to the completion of existing collaborations.
Read more →CTMX▼ -5.6%on this news
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
CytomX Therapeutics, Inc. will announce its second quarter financial results on August 7, 2025. The announcement will occur after the close of U.S. markets, followed by a conference call and webcast at 5:00 p.m. ET. Participants can access the live event through the company's website, with an archived replay available afterwards.
Read more →CTMX▲ +5%on this news
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
CytomX Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference on June 5, 2025. CEO Sean McCarthy will be involved in a fireside chat, which emphasizes the company's commitment to investor relations. Additionally, live webcasts will be available for interested parties, and one-on-one meetings will be offered to registered investors attending the event.
Read more →CTMXCytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma
CytomX Therapeutics has initiated dosing of the first patient in a Phase 1 clinical trial studying CX-801 in combination with KEYTRUDA for metastatic melanoma. CX-801 is designed to enhance the efficacy of interferon alpha-2b while minimizing systemic toxicities, potentially addressing unmet needs in patients with PD-1 refractory melanoma. The trial will evaluate both safety and initial clinical activity, with further translational and biomarker data expected later in 2025. However, the company faces risks regarding the unproven technology and the potential challenges inherent in clinical development.
Read more →CTMX▲ +129.4%on this news· ran to +169% by day 1
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in P
CytomX Therapeutics announced its first-quarter 2025 financial results, highlighting positive interim data from the Phase 1 study of CX-2051 in patients with advanced colorectal cancer. The company initiated dose expansions for CX-2051 and plans to begin a Phase 2 study in the first half of 2026. Revenue for the quarter rose to $50.9 million, attributed mainly to successful collaborations, though operational expenses showed a slight increase. CytomX aims to persist in its development of innovative cancer treatments while managing financial constraints.
Read more →CTMX▲ +129.4%on this news· ran to +169% by day 1
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
CytomX Therapeutics has announced the pricing for an underwritten offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million. The offering will close on May 13, 2025, pending customary conditions. The proceeds are intended for research and development, general corporate purposes, and working capital. Major investment firms led the offering and Jefferies and Piper Sandler are the joint book-running managers.
Read more →CTMX▲ +129.4%on this news· ran to +169% by day 1
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
CytomX Therapeutics announced positive interim results from a Phase 1 study of its EpCAM antibody drug conjugate, CX-2051, in patients with advanced colorectal cancer. The study reported a 28% confirmed response rate and a median progression-free survival of 5.8 months, with no dose limiting toxicities observed. The company plans to initiate a Phase 2 study in the first half of 2026, highlighting the potential growth in treating colorectal cancer and other malignancies expressing the EpCAM target. Safety data further supports the drug's favorable profile, suggesting a promising outlook for future development.
Read more →CTMX▲ +19.9%on this news· ran to +36% by day 3
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
CytomX Therapeutics, Inc. will report its first quarter financial results on May 12, 2025, before the U.S. markets open. A conference call and webcast will follow the announcement, allowing stakeholders to engage directly with the company's leadership. The live webcast can be accessed through CytomX's website, with an archived replay available afterward. This event is part of the company's ongoing commitment to financial transparency and investor communication.
Read more →CTMXCytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
CytomX Therapeutics has presented new preclinical data for an mRNA encoded masked IL-12 molecule developed in collaboration with Moderna, at the AACR Annual Meeting. This novel approach aims to activate the IL-12 within the tumor microenvironment, reducing systemic toxicity. The data is significant as it establishes proof of concept for the technology combination, vital for future developments in cancer therapy. However, the clinical use of IL-12 is limited due to inflammatory toxicity, which this new method intends to address.
Read more →CTMXCytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - Continued progress with lead program, CX-2051 (EpCAM PROBODY Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial P
CytomX Therapeutics has announced its 2024 financial results, focusing on the ongoing development of its lead program, CX-2051, which is currently in Phase 1a trials for advanced colorectal cancer. The company highlighted its financial stability, with cash reserves projected to last into the second quarter of 2026. Despite the positive outlook on CX-2051, the company has also made personnel cuts of about 40% to optimize capital allocation. The report includes updates on other pipeline programs and collaborations, indicating a balanced approach to advancing its clinical portfolio.
Read more →CTMX▼ -5.8%on this newsshared move
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
CytomX Therapeutics, Inc. announced its participation in the Barclays 27th Annual Global Healthcare Conference. The presentation, led by CEO Sean McCarthy, is scheduled for March 12, 2025. A live webcast will be available on the company's website, and management will offer one-on-one meetings with registered investors during the event.
Read more →CTMXCytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
CytomX Therapeutics, Inc. has announced that it will release its financial results for the full year of 2024 on March 6, 2025, following the close of U.S. markets. The company will hold a conference call and webcast at 5:00 p.m. ET to discuss the results. Participants are encouraged to register for the call in advance, and an archived version will be available on the company's website.
Read more →CTMXCytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CytomX Therapeutics, known for its work in masked, conditionally activated biologics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. CEO Sean McCarthy will lead the presentation at 1:30 p.m. PT. A live webcast will be available on the company's website, and management will also meet with registered investors.
Read more →CTMXCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
CytomX Therapeutics has outlined its strategic pipeline priorities for 2025, focusing on the advancement of CX-2051 for advanced metastatic colorectal cancer. The company announced it would streamline operations, leading to a significant reduction in headcount to allocate more resources to its promising clinical programs. Initial clinical data for CX-2051 will be available in the first half of 2025, and a cost reduction strategy is expected to extend their financial runway into the second quarter of 2026. CytomX is also engaged in ongoing collaborations to enhance its research and development capabilities.
Read more →CTMXCytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics, Inc. will participate in the 36th Annual Piper Sandler Healthcare Conference, with CEO Sean McCarthy set to take part in a fireside chat on December 4, 2024. The company will provide a live webcast of the event, allowing broader access to its discussion. Additionally, registered investors will have the chance for one-on-one meetings with CytomX management, emphasizing their commitment to investor relations.
Read more →CTMXCytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY T-cell engager) continues to advance. Potential Phase 1b initiation in
CytomX Therapeutics reported its third quarter 2024 financial results alongside a business update highlighting progress in its clinical pipeline. The company has advanced the Phase 1a dose escalation for CX-904 and is set to initiate potential Phase 1b studies in 2025. Additionally, the Phase 1 study for CX-2051 is ongoing with positive safety indicators, and CX-801 has also begun its first patient dosing. However, the company faces rising research and operational costs, alongside a decrease in cash reserves.
Read more →CTMXCytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CytomX Therapeutics has announced that it will disclose its third quarter financial results on November 7, 2024, following the close of U.S. markets. The company will subsequently conduct a conference call and webcast at 5:00 p.m. ET to discuss these results. Participants can access the live event through the company's website, where a replay will be made available afterward.
Read more →CTMXCytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY , in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics has announced the dosing of the first patient with its investigational product CX-801 in a Phase 1 trial focusing on patients with solid tumors. This innovative treatment integrates a dually-masked interferon alpha-2b PROBODY designed to enhance the therapeutic index while reducing toxicities. The study aims to evaluate the safety and potential clinical activity of CX-801 as a standalone treatment and in conjunction with Merck's KEYTRUDA anti-PD-1 therapy. The initial results could pave the way for expanding into more indication-specific cohorts in subsequent phases.
Read more →CTMXCytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - CX-904 (EGFR-CD3 PROBODY T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Progra
CytomX Therapeutics reported its Q2 2024 financial results, highlighting continued enrollment in its CX-904 Phase 1a trial focused on multiple cancer types. Initial data from CX-904 showed promising anti-cancer activity, particularly in pancreatic cancer. The company is also advancing its CX-2051 and CX-801 programs, with initial data anticipated in the coming years. Financially, CytomX holds $137.2 million in cash, supporting ongoing research and development efforts.
Read more →CTMXCytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
CytomX Therapeutics, Inc. has announced that it will report its second quarter financial results on August 8, 2024, after U.S. markets close. Following the announcement, the company will host a conference call and webcast at 5:00 p.m. ET. Interested participants can access the live webcast via the company's website, where an archived replay will also be available.
Read more →CTMX▼ -5.8%on this news
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CytomX Therapeutics, Inc. announced that CEO Sean McCarthy will participate in a fireside chat at the 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024. The presentation will include a live webcast accessible via the company's website. Additionally, CytomX management will hold one-on-one meetings with registered investors attending the conference.
Read more →CTMXCytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
CytomX Therapeutics has announced the promotion of Chris Ogden to Chief Financial Officer, effective June 15, 2024. Ogden, who joined the company in 2021, has extensive experience in financial leadership, including positions at Eli Lilly. The leadership change is seen as an opportunity to enhance the company's strategy for developing innovative cancer therapies, particularly through its PROBODY platform. However, the company acknowledges several risks and uncertainties regarding the advancement and success of its clinical programs.
Read more →CTMXCytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics, a leader in biologics, announced the grant of stock options to two new employees, totaling 130,000 shares at an exercise price of $1.96. This grant is under its Employment Inducement Incentive Plan, designed to attract new talent to the company. Such initiatives may indicate a strategic effort to bolster the workforce and drive future growth.
Read more →CTMXCytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid t
CytomX Therapeutics reported its first quarter 2024 financial results, announcing promising initial Phase 1a dose escalation data for its monotherapy CX-904 T-cell engager in solid tumors. The positive results highlight encouraging safety and anti-cancer activity. The company also reported milestones achieved through partnerships, particularly a $10 million success under its agreement with Astellas. Additionally, CytomX continues to advance its other programs, with initial data from clinical tests on CX-2051 and CX-801 anticipated in 2025.
Read more →CTMXCytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY T-Cell Engager) - CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CR
CytomX Therapeutics announced positive initial data from the Phase 1a clinical study of CX-904, a T-cell engager targeting EGFR, which showed a favorable safety profile and promising efficacy in advanced pancreatic cancer. Of the patients treated, 33% experienced a confirmed partial response, and all patients achieved disease control. The trial continues with ongoing dose escalation and optimization, and CytomX aims to provide further updates by the end of 2024. Management will host a conference call to discuss these results and future strategies.
Read more →CTMX▼ -6.9%on this news· ran to -55% by day 3shared move
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab)
CytomX Therapeutics has announced a clinical collaboration with Merck to evaluate CX-801, an interferon-alpha2b cytokine, in combination with KEYTRUDA for patients with advanced metastatic solid tumors. The Phase 1 first-in-human study is anticipated to commence in the first half of 2024. CX-801 aims to overcome the limitations of traditional interferon therapies by activating immune responses in the tumor microenvironment. This partnership could position CX-801 as a cornerstone in immuno-oncology treatment regimens.
Read more →CTMX▲ +214.7%on this news
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
CytomX Therapeutics, Inc. (Nasdaq: CTMX) will announce first quarter 2024 results and provide an initial update on the CX-904 Phase 1a clinical trial on May 8, 2024. This announcement will follow the close of U.S. markets and will be accompanied by a conference call at 5 p.m. EDT. The company is focused on advancing its masked biologic therapeutics, demonstrating its leadership in the field with ongoing clinical studies.
Read more →CTMXCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
CytomX Therapeutics has announced that the first patient has been dosed with CX-2051 in a Phase 1 clinical study targeting advanced solid tumors. CX-2051 is a PROBODY antibody-drug conjugate designed to specifically kill EpCAM-expressing tumors, which are common in several cancer types such as colorectal and ovarian cancer. The trial aims to evaluate safety and preliminary anti-tumor activity, potentially leading to dose expansions in 2025, emphasizing the company's commitment to addressing unmet medical needs in oncology.
Read more →CTMXCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
CytomX Therapeutics has announced the nomination of its second clinical candidate in a collaboration with Astellas, which has triggered a $5 million milestone payment. This achievement marks the third milestone in their ongoing partnership, which focuses on developing conditionally activated T-cell engaging bispecific therapies. CytomX retains co-commercialization rights for selected programs, emphasizing its strategic position within this collaboration. Both companies express optimism about the future potential of their combined immuno-oncology efforts.
Read more →CTMXCytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
CytomX Therapeutics has appointed Dr. Zhen Su to its board of directors, enhancing its leadership team in the oncology field. Dr. Su brings nearly 30 years of executive experience in oncology, having held significant roles at various biopharma companies. His expertise will likely influence CytomX's strategy and support its innovative PROBODY therapeutic pipeline aimed at addressing significant unmet needs in cancer treatment. This appointment underscores the company's commitment to developing safer, more effective therapies for patients.
Read more →CTMXCytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
CytomX Therapeutics announced a significant milestone in its collaboration with Astellas, triggering a $5 million payment due to the initiation of GLP toxicology studies for its first clinical candidate. This marks the first PROBODY T-cell engaging bispecific (TCB) molecule from the partnership to advance into toxicology studies. The companies continue collaborating on multiple projects, with CytomX eligible for additional milestones and retaining options for co-commercialization on select programs. The progress indicates a positive trajectory toward a potential Investigational New Drug (IND) application.
Read more →CTMXCytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (Ep
CytomX Therapeutics has reported its 2023 financial results, emphasizing key developments in its therapeutic pipeline. The company anticipates initial Phase 1a dose escalation data for CX-904 in the second half of 2024, alongside the initiation of Phase 1 studies for CX-2051 and CX-801 in the first half of 2024. Despite the encouraging progress, Bristol Myers Squibb has opted not to advance one of their joint ventures, BMS-986288, further in development. Overall, CytomX continues to maintain a strong financial position while focusing on its oncology research collaborations and pipeline expansions.
Read more →CTMXCytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
CytomX Therapeutics, Inc. has announced it will release its financial results for the full year 2023 on March 11, 2024, after U.S. markets close. Following this announcement, the company will hold a conference call and webcast for investors at 5:00 p.m. ET. Participants can access the event through the company's website, and a recording will be provided afterwards.
Read more →CTMX▲ +36.4%on this news· ran to +61% by day 3
CytomX Therapeutics to Present at Upcoming March Investor Conferences
CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced its participation in several investor conferences in March 2024, including the TD Cowen’s 44th Annual Health Care Conference and the Barclays 26th Annual Global Healthcare Conference. The events will feature formal presentations and a fireside chat, which will be accessible via live webcasts on the company's website. Additionally, CytomX's management will be available for one-on-one meetings with registered investors.
Read more →CTMXCytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
CytomX Therapeutics announced FDA clearance for its IND applications for CX-2051 and CX-801, which are set to begin Phase 1 clinical trials in the first half of 2024. CX-2051 is an EpCAM-directed antibody drug conjugate, while CX-801 is a conditionally activated interferon alpha-2b. Both products aim to address unmet needs in oncology, with CX-2051 specifically targeting colorectal cancer and CX-801 potentially enhancing combination therapies. This development reflects CytomX's commitment to innovative cancer treatments.
Read more →CTMXCytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
CytomX Therapeutics has announced that its CEO, Sean McCarthy, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Conference scheduled for January 18, 2024. This event provides an opportunity for the company to showcase its advancements in the field of conditionally activated localized biologics to potential investors. The conference is set to enhance CytomX’s presence and engagement within the oncology investment community.
Read more →CTMXCytomX Therapeutics Outlines 2024 Company Priorities and Milestones
CytomX Therapeutics has outlined its priorities and milestones for 2024, including the expected initiation of clinical trials for several of its investigational drugs. Key developments include the anticipated Phase 1 trials for CX-2051 and CX-801, both aimed at treating various cancers, and continued progress on the CX-904 T-cell engager. The company is strategically positioned to leverage its partnerships for advancing its pipeline, reflecting a strong commitment to addressing unmet medical needs in oncology. Financially, CytomX is well-prepared with cash reserves extending into 2025, supporting its ongoing projects.
Read more →CTMX▲ +5.2%on this news· ran to +16% by day 3
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CytomX Therapeutics, a leader in localized biologics, has announced that its CEO, Sean McCarthy, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The event highlights the company's commitment to engaging with investors and showcasing its innovations in the biotech field. A live webcast of the presentation will be available on the company's website, along with a replay for those unable to attend. Additionally, management will hold one-on-one meetings with registered investors at the conference.
Read more →CTMXCytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpC
CytomX Therapeutics reported its third quarter 2023 financial results, highlighting ongoing progress on multiple drug candidates. The company anticipates initial Phase 1 dose escalation data for CX-904 in early 2024, alongside IND filings for both CX-2051 and CX-801 by year-end 2023. CytomX has effectively managed its financial resources while advancing its pipeline, with significant milestones expected in 2024 and 2025. Additionally, collaborative efforts continue with major partners such as Bristol Myers Squibb, Amgen, and Moderna.
Read more →CTMXCytomX Therapeutics to Present at Upcoming November Investor Conferences
CytomX Therapeutics, Inc. announced its participation in several investor conferences scheduled for November. Key events include the BMO Biopharma Spotlight Series on Oncology Day, the Jefferies London Healthcare Conference, and the Piper Sandler Healthcare Conference. The management will offer fireside chats and one-on-one meetings with registered investors. Live webcasts of the presentations will also be available on their website.
Read more →CTMXCytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
CytomX Therapeutics, Inc. has announced it will report its third quarter financial results on November 7, 2023. The report will be released after U.S. markets close, followed by a conference call and webcast for investors. This event highlights the company's commitment to transparency and communication with stakeholders.
Read more →CTMXCytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting
CytomX Therapeutics announced the upcoming presentation of preclinical data for CX-801 at the SITC Annual Meeting in San Diego. This data supports the potential efficacy of their conditionally activated cytokine program, particularly in combination with checkpoint blockade. The company aims to file an Investigational New Drug (IND) application for CX-801 by the end of 2023, indicating a positive trajectory for their product development pipeline.
Read more →CTMXCytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
CytomX Therapeutics presented the preclinical profile of its EpCAM-directed antibody drug conjugate CX-2051 at the 2023 World ADC Conference. The data indicated that CX-2051 has the potential to effectively target EpCAM-expressing tumors, particularly colorectal cancer, while minimizing toxicity. An Investigational New Drug (IND) filing is expected by the end of 2023, with Phase 1 trials slated to begin in 2024, prioritizing metastatic colorectal cancer. CEO Marcia P. Belvin highlighted the design's intent to address unmet patient needs and mitigate dose-limiting toxicities associated with traditional therapies.
Read more →CTMXCytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
CytomX Therapeutics, a leader in localized biologics, will present at the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17. CEO Sean McCarthy will lead the presentation, which will be accessible via live webcast. Additionally, CytomX management is set to hold one-on-one meetings with registered investors during the event.
Read more →CTMXCytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-di
CytomX Therapeutics reported its second quarter 2023 financial results, highlighting a robust financial position following a strategic financing round. The company anticipates initial Phase 1 dose escalation data for CX-904 in the first half of 2024 and plans for IND filings for CX-2051 and CX-801 by Q4 2023. Additionally, recent management additions and ongoing partnerships are poised to enhance the development of its Probody Therapeutic pipeline. Despite some revenue setbacks, CytomX appears on a solid trajectory for future growth with several upcoming clinical milestones.
Read more →CTMXCytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
CytomX Therapeutics, Inc. has announced that it will report its financial results for the second quarter of 2023 on August 8, 2023, after U.S. markets close. Following the report, the company will host a conference call and a webcast to discuss the results. Participants are encouraged to register in advance for the call, which reflects the company’s commitment to investor engagement and transparency.
Read more →CTMXCytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
CytomX Therapeutics has appointed Dr. Yu-Waye (Wayne) Chu as its new Chief Medical Officer, bringing over 20 years of experience in oncology. Dr. Chu will oversee the development of CytomX's portfolio, including its Probody® therapeutic candidates. His background includes leadership roles in clinical development strategies at various biopharma companies. The appointment comes at a significant time as CytomX aims for clinical progress with multiple candidates in its pipeline.
Read more →CTMX▲ +22%on this news
CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
CytomX Therapeutics has announced a $30 million private placement with BVF Partners L.P., aimed at enhancing its financial position. The funding is expected to extend the company's cash runway into the second half of 2025, allowing for the pursuit of multiple clinical milestones. The investment includes pre-funded warrants to purchase up to 14.4 million shares at a price that represents a premium to the recent trading price. CytomX will also be able to potentially receive an additional $60 million if all associated warrants are exercised.
Read more →CTMXCytomX Therapeutics to Present at the Jefferies Healthcare Conference
CytomX Therapeutics announced that its CEO, Sean McCarthy, will present at the upcoming Jefferies Healthcare Conference on June 8. The event will include a live webcast of the presentation, accessible on the company's website. Additionally, CytomX management will hold one-on-one meetings with registered investors during the conference, indicating engagement with stakeholders.
Read more →CTMXCytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-
CytomX Therapeutics reported its first quarter 2023 financial results, showcasing advancements in their pipeline, including CX-904's Phase 1 dose escalation. The company is on track with IND filings for CX-2051 and CX-801, backed by a $5 million milestone payment from Astellas. However, it faced a setback as AbbVie terminated the CD71 collaboration for CX-2029. Overall, CytomX is focused on aggressive growth and maintaining a robust balance sheet amidst challenges.
Read more →CTMX▲ +5.5%on this news
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
CytomX Therapeutics, Inc. has announced that it will report its first quarter financial results on May 9, 2023, after U.S. market close. Following the results announcement, the company will hold a conference call and webcast at 5:00 p.m. ET. Interested participants can access the live webcast through the company’s Events and Presentations webpage. There will also be an archived replay of the webcast available thereafter.
Read more →CTMXCytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
CytomX Therapeutics, a leader in localized biologics, announced that its CEO, Sean McCarthy, will present at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. A live webcast of the chat will be available for stakeholders. Additionally, management will hold one-on-one meetings with registered investors. This engagement emphasizes the company's commitment to communicating with investors about its developments.
Read more →CTMX▲ +5.3%on this news
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filin
CytomX Therapeutics has reported its full year 2022 financial results and provided an optimistic business update. The company focuses on its next-generation therapeutic pipeline, including ongoing clinical trials for CX-904 and expected IND submissions for CX-801 and CX-2051 later in 2023. Additionally, collaborations with major companies like Moderna and Regeneron have been established to enhance their therapeutic offerings, despite the setback with the CX-2029 program. The company is navigating restructuring to maximize long-term growth and value creation.
Read more →CTMXCytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
CytomX Therapeutics, Inc. has announced that it will report its full year 2022 financial results on March 27, 2023. The announcement includes details about a conference call that will follow the results release, allowing participants to access the live event and a recorded replay afterward. This reporting is part of the company's ongoing effort to keep investors informed about its financial performance.
Read more →CTMX▲ +6.1%on this news
CytomX Therapeutics Announces Milestone Achievement in Probody T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
CytomX Therapeutics announced the achievement of a significant milestone in its collaboration with Astellas, marking the first clinical candidate from their TCB agreement. This achievement triggers a $5 million milestone payment to CytomX. The companies will continue to work together on additional T-cell engaging programs, with CytomX retaining commercial rights on select targets. The announcement highlights both the promise of localized T-cell therapies and the challenges inherent in clinical development.
Read more →CTMX▼ -6.6%on this news
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
CytomX Therapeutics, Inc. has announced that its CEO, Sean McCarthy, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on January 19, 2023. The presentation will be available via a live webcast, and an archived version will be accessible for 30 days post-event. Additionally, registered investors will have the chance to meet one-on-one with the management team during the conference.
Read more →CTMX▲ +7.2%on this news· ran to +66% by day 3
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
CytomX Therapeutics and Moderna have entered into a strategic collaboration to develop mRNA-based conditionally activated therapeutics. Under the agreement, CytomX will receive an upfront payment of $35 million and could earn additional milestone payments totaling approximately $1.2 billion. The partnership aims to integrate CytomX's Probody platform with Moderna's mRNA technology, potentially leading to innovative treatments in oncology and beyond. Moderna will oversee clinical development and commercialization while potentially participating in future equity financing from CytomX.
Read more →CTMX▲ +7.2%on this news· ran to +66% by day 3
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
CytomX Therapeutics has announced its priorities for 2023, highlighting progress on its drug candidate CX-2029, which showed promising anti-cancer activity in recent trials. The company is expanding its operations with a new collaboration with Moderna and is set to advance its development pipeline, including two new IND filings. While there were notable treatment-related adverse events, such as anemia, the overall sentiment around the pipeline remains positive, with expectations for further advancements in cancer therapies this year.
Read more →CTMXCytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for
Read more →CTMXCytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will pre
Read more →CTMXCytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate (ADC)
Read more →CTMX▲ +32.2%on this news· ran to +58% by day 3
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, developme
Read more →CTMXCytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interf
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904
Read more →CTMXCytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be
Read more →CTMXCytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022,
Read more →CTMX▲ +6.9%on this news
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody Therapeutic BMS-986249
- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb - - BMS-986249 Phase 2 study ongoing - SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeut
Read more →CTMXCytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
- Presentation at World ADC Conference in San Diego - - CX-2051 integrates CytomX core platform expertise to potentially maximize therapeutic window - SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field
Read more →CTMXCytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update - Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated t
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update - Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 - - New INDs f
Read more →CTMXCytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will virtually parti
Read more →CTMXCytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022,
Read more →CTMXCytomX Therapeutics Provides Strategic Update
- Company to focus internal efforts on wholly-owned next-generation conditionally activated therapeutics, including IFN alpha-2b cytokine and EpCAM-directed ADC, INDs planned for 2023 - - Partnered clinical-stage programs continue to advance: Phase 2 programs, BMS-986249 (anti-C
Read more →CTMXCytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer - - Secondary endpoints including clinical benefit rate at 24 weeks and median progression-free survival were 40 percent and 2.6 months, respectively - - Arm B did not pass protoco
Read more →CTMXCytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the
Read more →CTMXCytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT0
Read more →CTMX▼ -5.8%on this news
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for bot
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 - - Phase
Read more →CTMXCytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, aft
Read more →CTMXCytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when hi
Read more →CTMXCytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th,
Read more →CTMX▲ +15.7%on this news
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data supporting the ongoing development of its conditionally activate
Read more →CTMX▼ -7.6%on this news
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update - Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC)
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update - Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 - - First-in-human study of CX-904 in ad
Read more →CTMXCytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in
Read more →CTMXCytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, Mar
Read more →CTMXCytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the promotion of Amy C. Peterson, M.D., to the position of president and chief operatin
Read more →CTMX▲ +6.5%on this newsshared move
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New D
Read more →CTMX2022 CytomX Therapeutics, Inc.
2022 CytomX Therapeutics, Inc. 40 th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman January 12, 2022 Forward - Looking Statements This presentation may contain projections and other forward - looking statements re
Read more →CTMXCytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virt
Read more →CTMXCytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
-Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues- -Enrollment completed in advanced head and neck squamous cell carcinoma with objective response rate of 4.0 percent
Read more →CTMXCytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Pha
CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update -Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine (CX-2009) expected
Read more →CTMXCytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology p
Read more →CTMX▲ +8.4%on this newsshared move
CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology p
Read more →CTMXCytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology p
Read more →CTMXCytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology
Read more →CTMXCytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 5, 2021 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investig
Read more →CTMXCytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)
-Translational whole-body PET clinical imaging supports conditional activation in the tumor microenvironment- -Pacmilimab demonstrated single-agent activity in advanced solid tumors, including metastatic triple-negative breast cancer- -Combination of pacmilimab and ipilimumab i
Read more →CTMXCytomX Therapeutics to Present at Upcoming August Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® tec
Read more →CTMXCytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology p
Read more →CTMXCytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology p
Read more →CTMXCytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology pl
Read more →CTMXCytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 6, 2021 - CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigat
Read more →CTMXCytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® te
Read more →CTMXCytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® t
Read more →CTMXCytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launch
CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollment continues in Phase 2 exp
Read more →CTMXCytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody® techn
Read more →CTMXCytomX Therapeutics Announces New Employment Inducement Grant
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody® techno
Read more →CTMXCytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody® techno
Read more →CTMXCytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today
Read more →CTMXCytomX Therapeutics Announces Closing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the completion of its pre
Read more →CTMXCytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the pricing of an underwr
Read more →CTMXCytomX Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has commenced an
Read more →CTMXCytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today
Read more →CTMXCytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today
Read more →CTMXCytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today
Read more →CTMXCytomX Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today
Read more →CTMXCytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Company to host a conference call today
CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, CA, November 5, 2020- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clin
Read more →CTMXCytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today
Read more →CTMXCytomX Therapeutics to Announce Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology plat
Read more →CTMXCytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.
Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research Dr. Kavanaugh to Join CytomX Scientific Advisory Board SOUTH SAN FRANCISCO, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharm
Read more →CTMXCytomX Therapeutics to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology pla
Read more →CTMXCytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today
CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PT SOUTH SAN FRANCISCO, CA, August 6, 2020- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinica
Read more →CTMXCytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology plat
Read more →CTMXCytomX Therapeutics to Announce Second Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology plat
Read more →CTMXCytomX Investors: Last Days to Seek Participation in Class Action as Lead Plaintiff
LOS ANGELES, July 16, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CytomX Therapeutics, Inc. investors (NASDAQ: CTMX) (“CytomX” or the “Company”) that acquired CytomX securities between May 17, 2018, and M
Read more →CTMXCytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 and BMS-986288, anti-CTLA-4 Probody therapeutics generated with CytomX’s novel
Read more →CTMXCytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
- First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate, Directed Against CD71: A Previously Undruggable Target - - Data Updates for CX-2009 Support Phase 2 Investigations in Breast Cancer - - Favorable Tolerability Profile Demonstrated for Anti-PD-L1 and A
Read more →CTMXCytomX Therapeutics to Participate at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platf
Read more →CTMXCytomX Therapeutics to Host Conference Call and Webcast to Review ASCO ASCO20 Virtual Scientific Program Presentations
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platf
Read more →CTMXCytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platf
Read more →CTMXCytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today
CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, May 7, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, CA, May 7, 2020- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
Read more →CTMXCytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platf
Read more →CTMXCytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program
- 7 Abstracts Highlighting CytomX’s Novel Probody Platform Selected for Oral and Poster Presentations - SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneerin
Read more →CTMXCytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology pla
Read more →CTMXCytomX Therapeutics to Announce First Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology pla
Read more →CTMXCytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline
Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX Clinical Studies for CX-2009 and CX-072 impacted by Global COVID-19 Pandemic, Prompting Pipeline Reprioritization Co
Read more →CTMXCytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody T-Cell Engaging Bispecific Therapies for Treatment of Cancer
- Collaboration to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets - - CytomX to Receive $80 Million Upfront Payment and Ability to Exercise Option for U.S. Co-Commercialization Rights - SOUTH SAN FRANCISCO, Calif. and TOKYO, March 23, 2020 (GLOB
Read more →CTMXCYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER
SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology pla
Read more →CTMXCytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update Company to Host a Conference Call Today
CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update Company to Host a Conference Call Today, February 27, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, CA, February 27, 2020- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinic
Read more →CTMXCytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology plat
Read more →CTMXCytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology plat
Read more →CTMXCytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology plat
Read more →CTMXCytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook
- Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies – - Partnered Clinical Programs Advancing - - Multiple Updates Anticipated Across Portfolio in 2020 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT
Read more →CTMXCytomX Therapeutics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics Announces Third Quarter 2019 Financial Results -Company to Host a Conference Call Today
CytomX Therapeutics Announces Third Quarter 2019 Financial Results -Company to Host a Conference Call Today, November 7, 2019, at 5:00 p.m. ET / 2:00 p.m. PT- SOUTH SAN FRANCISCO, CA, November 7, 2019- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused
Read more →CTMXCytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY in Patients with Relapsed or Refractory Melanoma
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics to Announce Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer
-Industry Veteran Joins to Advance Maturing Platform and Pipeline to Next Phase of Development- -Product Development Team Further Strengthened with Appointment of Glenn Michelson, M.D., as Vice President, Clinical Development and Jason Braun, MBA, as Vice President, Commercial S
Read more →CTMXCytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update -Company to Host a Conference Call Today
CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update -Company to Host a Conference Call Today, August 7, 2019, at 5:00 p.m. ET / 2:00 p.m. PT- SOUTH SAN FRANCISCO, CA, August 7, 2019- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clini
Read more →CTMXCytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics to Announce Second Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
SOUTH SAN FRANCISCO, Calif., July 09, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif., June 01, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused
Read more →CTMXCytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platfor
Read more →CTMXCytomX Therapeutics Announces First Quarter 2019 Financial Results Company to Host a Conference Call Today
CytomX Therapeutics Announces First Quarter 2019 Financial Results Company to Host a Conference Call Today, May 9, 2019, at 5:00 p.m. EDT / 2:00 p.m. PDT SOUTH SAN FRANCISCO, CA, May 9, 2019- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmac
Read more →CTMXCytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics to Announce First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of Directors
CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of Directors SOUTH SAN FRANCISCO, Calif., April 22, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody ther
Read more →CTMXCytomX Therapeutics Announces Transition of Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology pla
Read more →CTMXCytomX to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology pla
Read more →CTMXCytomX Therapeutics Announces Full-Year 2018 Financial Results -Company to Host a Conference Call Today
CytomX Therapeutics Announces Full-Year 2018 Financial Results -Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST- SOUTH SAN FRANCISCO, CA., February 27, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focus
Read more →CTMXCytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody Therapeutic Platform - CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166
CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody Therapeutic Platform SOUTH SAN FRANCISCO, CA., February 26, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused bi
Read more →CTMXCytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call
-Teleconference Scheduled for February 27, 2019, at 5:00 p.m. ET- -Company to Host Research and Development Day on February 26, 2019 in New York City- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncolo
Read more →CTMXCytomX Therapeutics Announces Senior Management Appointments
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics to Host Research and Development Day on February 26, 2019
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology plat
Read more →CTMXCytomX Therapeutics Announces Technology Acquisition From Agensys, Inc., an Affiliate of Astellas Pharma Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics Announces Changes to its Board of Directors - President and CEO Sean McCarthy, D. Phil., Appointed to Additional Role of Chairman - - Hoyoung Huh, M.D., Ph.D. Retiring from Board - - James R. Meyers,
CytomX Therapeutics Announces Changes to its Board of Directors - President and CEO Sean McCarthy, D. Phil., Appointed to Additional Role of Chairman - - Hoyoung Huh, M.D., Ph.D. Retiring from Board - - James R. Meyers, Former EVP at Gilead Sciences Inc., Appointed to Board -
Read more →CTMXCytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting
- Demonstrates Further Proof-of-Mechanism of Probody™ Platform – - Consistent with CX-072 Clinical Observations at 2018 ASCO and ESMO Presentations- - Company to Host Analyst and Investor Event and Webcast Tomorrow, Saturday, November 10th - SOUTH SAN FRANCISCO, Calif., Nov. 0
Read more →CTMXCytomX to Present at the Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics Announces CX-072 Clinical Presentations at 2018 SITC Annual Meeting
PROCLAIM-CX-072 Clinical Translational Data Presented as Poster and Rapid-Fire Oral Presentation Company to Host Analyst and Investor Event and Webcast SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) a clinical-stage oncol
Read more →CTMXCytomX Therapeutics Announces Third Quarter 2018 Financial Results - ESMO Presentations Support CX-072 Product Profile and Probody Proof-of-Concept - - Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-20
CytomX Therapeutics Announces Third Quarter 2018 Financial Results SOUTH SAN FRANCISCO, Calif., November 6, 2018 - CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeu
Read more →CTMXCytomX Therapeutics to Announce Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platf
Read more →CTMXForward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of
PROCLAIM CX-072 ESMO 2018 Clinical Presentations October 22, 2018 Exhibit 99.1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements othe
Read more →CTMXCytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting
- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host Conference Call and Webcast Today, Monday, October 22nd at 2:30 p.m. CEST /8:30 a.m. EDT - SOUTH SAN FRANCIS
Read more →CTMXCytomX Therapeutics Announces Presentations at 2018 ESMO Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platfo
Read more →CTMXCytomX Therapeutics Announces Second Quarter 2018 Financial Results - Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (
CytomX Therapeutics Announces Second Quarter 2018 Financial Results SOUTH SAN FRANCISCO, Calif., August 8, 2018 - CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutic
Read more →CTMXCytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics to Announce Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platf
Read more →CTMXCytomX Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platf
Read more →CTMXCytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel
SOUTH SAN FRANCISCO, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platfo
Read more →CTMXCytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting
– PD-L1 Targeting Probody CX-072 Well Tolerated and Shows Antitumor Activity as Monotherapy and in Combination with Ipilimumab – – Company to Host Conference Call and Webcast Today Monday, June 4th at 5:00 p.m. CT / 6:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLO
Read more →CTMXCytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platfo
Read more →CTMXCytomX to Present at the Jefferies 2018 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platfo
Read more →CTMXCytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platfor
Read more →CTMXCytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platfor
Read more →CTMXCytomX Therapeutics Announces First Quarter 2018 Financial Results - Initial clinical data from the Phase 1/2 CX-072 program to be reported at American Society of Clinical Oncology Annual Meeting
CytomX Therapeutics Announces First Quarter 2018 Financial Results SOUTH SAN FRANCISCO, Calif., May 9, 2018 - CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics ba
Read more →CTMXCytomX to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platfo
Read more →CTMXCytomX Therapeutics to Announce First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report first quarter 2018 financial results on
Read more →CTMXCytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update SOUTH SAN FRANCISCO, Calif., March 7, 2018 (GLOBE NEWSWIRE) - CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody the
Read more →CTMXCytomX to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two
Read more →CTMXCytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report full-year 2017 financial results and pr
Read more →CTMXCytomX Therapeutics Added to NASDAQ Biotechnology Index
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company has been added to the
Read more →CTMXCytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic Goal is a safer, more effective version of Yervoy Triggers $10 Million Milestone Payment to CytomX from
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic Goal is a safer, more effective version of Yervoy Triggers $10 Million Milestone Payment to CytomX from Bristol Myers Squibb NEW YORK, NY and SOUTH SAN FRANCISCO
Read more →CTMXCytomX Announces Third Quarter 2017 Financial Results and Operational Progress
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress SOUTH SAN FRANCISCO, Calif., November 7, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment
Read more →CTMXCytomX to Present at the Jefferies 2017 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2017 London Healthcare Conference. Sean
Read more →CTMXCytomX Therapeutics to Announce Third Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the third quarter ended September
Read more →CTMXCytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to SOUTH SAN FRANCISCO, Calif., October 24, 2017 (GLOBE NEWSWIRE) - CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today an
Read more →CTMXCytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that preclinical results will be presented at the 2017
Read more →CTMXAMGEN AND CYTOMX THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY Companies to Jointly Develop T-Cell Engaging Bispecific Probody THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. (
AMGEN AND CYTOMX THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY Companies to Jointly Develop T-Cell Engaging THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. (Oct. 3, 2017) Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced
Read more →CTMXCytomX to Present at the Cantor Fitzgerald Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Cantor Fitzgerald Healthcare Conference. Sean Mc
Read more →CTMXCytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced upcoming Trials in Progress poster presentations for
Read more →CTMXCytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the 2017 Wedbush PacGrow Healthcare Conference. Deban
Read more →CTMXCytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call Strong Pipeline Momentum Continues Initiated Combination Arms in Phase 1/2 PROCLAIM-CX-072 Study Initiated Phase 1/2 PROC
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call Strong Pipeline Momentum Continues Initiated Combination Arms in Phase 1/2 PROCLAIM-CX-072 Study Initiated Phase 1/2 PROCLAIM-CX-2009 Study SOUTH SAN FRANCISCO, Calif., August 7
Read more →CTMXCytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30,
Read more →CTMXCytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate
CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate SOUTH SAN FRANCISCO, Calif., June 29, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investig
Read more →CTMXCytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial
CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment o
Read more →CTMXCytomX to Present at the Jefferies 2017 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2017 Global Healthcare Conference. Sean M
Read more →CTMXCytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced an upcoming poster presentation for its lead product ca
Read more →CTMXCytomX Announces Management Team Changes
SOUTH SAN FRANCISCO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that Bob Goeltz, chief financial officer, has decided t
Read more →CTMXCytomX Announces First Quarter 2017 Financial Results
CytomX Announces First Quarter 2017 Financial Results SOUTH SAN FRANCISCO, Calif., May 5, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today reported fir
Read more →CTMXCytomX Therapeutics to Announce First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the first quarter ended March 31,
Read more →CTMXCytomX Therapeutics Appoints Marion McCourt to Board of Directors
CytomX Therapeutics Appoints Marion McCourt to Board of Directors SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today
Read more →CTMXBristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody Therapeutics for the Treatment of Cancer and Other Diseases • Builds upon initial 2014 alliance in oncology •
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody Therapeutics for the Treatment of Cancer and Other Diseases (NEW YORK and SOUTH SAN FRANCISCO, March 20, 2017) - Bristol-Myers Squibb Company (NYSE:BMY) and CytomX Therapeutics, Inc.
Read more →CTMXCytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update
SOUTH SAN FRANCISCO, Calif., March 19, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that members of the management team will host a telec
Read more →CTMXCytomX Announces Full-Year 2016 Financial Results
CytomX Announces Full-Year 2016 Financial Results SOUTH SAN FRANCISCO, Calif., March 2, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today reported full-
Read more →CTMXCytomX Therapeutics to Announce Full-Year 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report full-year 2016 financial results on March 2, 2017, af
Read more →CTMXCytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced the treatment of the first patient in the PROCLAIM (Pr
Read more →CTMXCytomX to Present at the 35th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the 35th Annual J.P. Morgan Healthcare Conference. Sea
Read more →CTMXCytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072
CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072 SOUTH SAN FRANCISCO, Calif., December 14, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical comp
Read more →CTMXCytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration CTLA-4 Probody Moves to IND-Enabling Studies
CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration CTLA-4 Probody Moves to IND-Enabling Studies SOUTH SAN FRANCISCO, Calif. - December 13, 2016 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company develop
Read more →CTMXCytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration Triggers $15 Million Milestone Payment to CytomX
CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration Triggers $15 Million Milestone Payment to CytomX SOUTH SAN FRANCISCO, Calif., December 5, 2016 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company develo
Read more →CTMXCytomX to Present at the Jefferies 2016 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2016 London Healthcare Conference. Sean
Read more →CTMXCytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update
CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for
Read more →CTMXCytomX Therapeutics to Announce Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the third quarter, ended September
Read more →CTMXCytomX Announces Second Quarter 2016 Financial Results
CytomX Announces Second Quarter 2016 Financial Results SOUTH SAN FRANCISCO, Calif., August 3, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today reported
Read more →CTMXCytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update
SOUTH SAN FRANCISCO, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30,
Read more →CTMXCytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors South San Francisco
CytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors South San Francisco, June 13, 2016 -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced that John
Read more →CTMXCytomX to Present at the Jefferies 2016 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 24, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2016 Healthcare Conference in New York, N
Read more →CTMXCytomX Announces First Quarter 2016 Financial Results
CytomX Announces First Quarter 2016 Financial Results SOUTH SAN FRANCISCO, Calif., May 6, 2016 - CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today reported financial results for
Read more →CTMXCytomX to Present at the 2016 Bank of America Merrill Lynch Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the 2016 Bank of America Merrill Lynch Healthcare Con
Read more →CTMXCytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates - Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71 - AbbVie to Receive the Right to
CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates - Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71 - AbbVie to Receive the Right to License Probody Drug Conjugates for up to Two Additional Undisclosed Ta
Read more →CTMXCytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates
- Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71 - AbbVie to Receive the Right to License Probody Drug Conjugates for up to Two Additional Undisclosed Targets - CytomX to Receive $30 Million Upfront Payment NORTH CHICAGO, Ill. and
Read more →CTMXCytomX Announces Data to be Presented at the American Association for Cancer Research Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that preclinical results from its Probody therapeutics pipe
Read more →CTMXCytomX Announces Year-End 2015 Financial Results
CytomX Announces Year-End 2015 Financial Results SOUTH SAN FRANCISCO, Calif., March 7, 2016 - CytomX Therapeutics, Inc. (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today reported year-end 2015 financial
Read more →CTMXCytomX to Present at Cowen and Company’s 36th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that it will present at Cowen and Company’s 36th Annu
Read more →CTMXCytomX Therapeutics, Inc. (Nasdaq:CTMX) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Feb. 23, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Sean McCart
Read more →CTMXCytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone Milestone Reflects Continued Momentum in Ongoing Collaboration
CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone Milestone Reflects Continued Momentum in Ongoing Collaboration SOUTH SAN FRANCISCO, Calif., January 20, 2016 - CytomX Therapeutics, Inc. (Nasdaq: CTMX), a biopharmaceutical company developing
Read more →CTMXCytomX Added to Russell 2000 Index
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that it has been added to the Russell 2000®, Russell 3
Read more →CTMXCytomX Selects Probody Drug Conjugate Clinical Candidate, CX-2009, Targeting Highly Expressed Tumor Antigen, CD166
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced that it has selected its second clinical candidate from
Read more →CTMXCytomX to Present at Oppenheimer's 26th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced that it will present at Oppenheimer's 26th Annual Health
Read more →CTMXCytomX Reports Third Quarter 2015 Financial Results
CytomX Reports Third Quarter 2015 Financial Results SOUTH SAN FRANCISCO, Calif., November 23, 2015 - CytomX Therapeutics, Inc. (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today reported financial result
Read more →CTMXCytomX Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
CytomX Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., October 14, 2015 CytomX Therapeutics, Inc. (Nasdaq: CTMX) (the Company ), a biopharmaceutical company developing Probody ther
Read more →Competitive Position
How CTMX ranks across every disease it competes inCompetitive Position is a premium feature
See how CTMX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial